Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024373 | 0.95 | TRPV4 (0.39) | TRPV4NR1H2NR1H3PSEN1PSEN2 | |
| SCHEMBL21191578 | 0.94 | TRPV4 (0.38) | TRPV4NR1H2NR1H3PSEN1PSEN2 | |
| SCHEMBL23634137 | 0.94 | TRPV4 (0.42) | TRPV4ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL22023804 | 0.91 | TRPV4 (0.40) | TRPV4ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL19388376 | 0.88 | TRPV4 (0.40) | TRPV4NR1H2NR1H3PSEN1PSEN2 | |
| SCHEMBL24876756 | 0.88 | TRPV4 (0.40) | TRPV4NR1H2NR1H3PSEN1PSEN2 | |
| SCHEMBL23845820 | 0.87 | TRPV4 (0.47) | TRPV4ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL21191574 | 0.87 | TRPV4 (0.39) | TRPV4ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL21123750 | 0.84 | TRPV4 (0.42) | TRPV4ESR1ESR2NR1H2NR1H3 | |
| SCHEMBL20031198 | 0.82 | HPGD (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | TRPV4 4179/4885ESR1 1800/4885ESR2 2576/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | TRPV4 1472/4885ESR1 755/4885ESR2 338/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TRPV4 4231/4885ESR1 1662/4885ESR2 2553/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TRPV4 4231/4885ESR1 1662/4885ESR2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.